CompletedNot Applicable

Efficacy and Safety of CONAN® Proctological Cream for Treatment of Haemorrhoidal Disease

Italy40 participantsStarted 2022-03-01

Plain-language summary

Aim of the study is to assess the efficacy, safety and tolerability of CONAN® (Proctological Cream, Medical Device, Omikron Italia Srl) on most frequent symptoms in grade 1-2 of haemorrhoidal disease and anal fissures.

Who can participate

Age range18 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Aged between 18 and 70 years * Hemorrhoidal pathology, anal fissures and anitis * NRS score ≥ 3 for at least one of the symptoms (burning, itching, feeling of heaviness, foreign body) Exclusion Criteria: * Known hypersensitivity to study products * Proctitis * Current therapy with other local treatments based on phlebotropes and/or anti-inflammatories * Surgical treatments undergone less than a year after inclusion * Pregnancy, breastfeeding

What they're measuring

Change in the symptom numerical rating scale

Timeframe: 30 days

Trial details

NCT IDNCT05984641

SponsorOmikron Italia S.r.l.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2022-08-29

View on ClinicalTrials.gov More Hemorrhoid Pain trials